Novo Nordisk AS signs a $2.1 billion licensing agreement
On October 15th, Danish pharmaceutical company Novo Nordisk and American biotechnology company Omeros announced that they have signed a licensing agreement worth up to $2.1 billion, under which Novo Nordisk will obtain a drug being developed by Omeros for the treatment of rare blood and kidney diseases
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments